Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Randomised, Double Blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety Over 48 Weeks of Orally Inhaled Tiotropium Bromide (2.5 and 5 µg Once Daily ) Delivered by the Respimat® Inhaler in Adolescents (12 to 17 Years Old) With Moderate Persistent Asthma.
Brief Summary: The aim of the study is to evaluate efficacy and safety of a 48-week treatment with two doses of tiotropium bromide compared to placebo in adolescent patients with moderate persistent asthma. Efficacy and safety will be assessed by measuring lung function parameters and evaluating the effects on asthma exacerbations, on Quality of life, on health care resource utilisation an on the number of adverse events.


Options:
A: Arm Label: MF/F 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: mometasone furoate combination MDI 200/10 mcg BID | Arm Label: MF/F 400/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: mometasone furoate combination MDI 400/10 mcg BID | Arm Label: F/SC 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone/Salmeterol 250/50 mcg BID | Arm Label: F/SC 500/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone/Salmeterol 500/50 mcg BID | Intervention Type: DRUG; Name: mometasone furoate combination MDI 200/10 mcg BID; Assigned to Arm(s): MF/F 200/10 mcg BID | Intervention Type: DRUG; Name: mometasone furoate combination MDI 400/10 mcg BID; Assigned to Arm(s): MF/F 400/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone/Salmeterol 250/50 mcg BID; Assigned to Arm(s): F/SC 250/50 mcg BID | Intervention Type: DRUG; Name: Fluticasone/Salmeterol 500/50 mcg BID; Assigned to Arm(s): F/SC 500/50 mcg BID
B: Arm Label: MF/F MDI 200/10 mcg BID; Type: EXPERIMENTAL; Interventions: Drug: Mometasone furoate/formoterol (MF/F) MDI | Arm Label: F/SC DPI 250/50 mcg BID; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/salmeterol (F/SC) DPI | Intervention Type: DRUG; Name: Mometasone furoate/formoterol (MF/F) MDI; Assigned to Arm(s): MF/F MDI 200/10 mcg BID | Intervention Type: DRUG; Name: Fluticasone propionate/salmeterol (F/SC) DPI; Assigned to Arm(s): F/SC DPI 250/50 mcg BID
C: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo Respimat | Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat high dose | Intervention Type: DRUG; Name: tiotropium Respimat low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo Respimat; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium Respimat high dose; Assigned to Arm(s): tiotropium high dose
D: Arm Label: Fluticasone furoate 50 mcg; Type: EXPERIMENTAL; Interventions: Drug: Fluticasone furoate 50mcg | Arm Label: Fluticasone propionate 100mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate 100mcg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Fluticasone furoate 50mcg; Assigned to Arm(s): Fluticasone furoate 50 mcg | Intervention Type: DRUG; Name: Fluticasone propionate 100mcg; Assigned to Arm(s): Fluticasone propionate 100mcg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C